<DOC>
	<DOCNO>NCT00009776</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining monoclonal antibody therapy cyclosporine paclitaxel may effective treatment non-Hodgkin 's lymphoma . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody therapy combine paclitaxel cyclosporine treat patient recurrent refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy , Paclitaxel , Cyclosporine Treating Patients With Recurrent Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90 monoclonal antibody Lym-1 combination paclitaxel cyclosporine patient recurrent refractory non-Hodgkin 's lymphoma . OUTLINE : This dose-escalation study yttrium Y 90 monoclonal antibody Lym-1 ( Y90 MOAB Lym-1 ) . Patients receive oral cyclosporine every 12 hour day -2 14 . Patients receive unlabeled MOAB Lym-1 IV follow tracer dose indium In 111 MOAB Lym-1 IV day 0 . On day 7 , patient receive unlabeled MOAB Lym-1 IV follow Y90 MOAB Lym-1 IV . Patients cohorts 2-4 also receive paclitaxel IV 3 hour day 9 . Courses repeat every 8 week total 3 course absence disease progression unacceptable toxicity . Cohorts 3 patient receive escalate dos Y90 MOAB Lym-1 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 patient experience dose-limiting toxicity . Patients follow monthly 3 month , every 3 month 21 month , every 6 month 3 year . PROJECTED ACCRUAL : A total 24 patient accrue study within 36 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonHodgkin 's lymphoma ( NHL ) fail standard firstline chemotherapy Measurable disease NHL tissue Lym1 reactive vitro Normocellular bone marrow evidence less 25 % bone marrow NHL bilateral bone marrow biopsy No bone marrow evidence myelodysplastic syndrome HAMA titer negative PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : 3 6 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 130,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST great 84 U/L Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : LVEF least 50 % Pulmonary : FEV1 least 60 % predict FVC least 60 % predict DLCO least 50 % Other : No prior malignancy within past 5 year except nonmelanoma skin cancer HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior external beam radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2001</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>